April 8, 2022

Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022

RESEARCH TRIANGLE PARK, N.C., April 8th, 2022 - Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 taking place the 8th-13th of April in New Orleans. The data demonstrate that BTM-3566 co-opts a specific mitochondrial quality control pathway to induce apoptosis in cell lines, xenografts and patient-derived xenograft (PDX) models of Diffuse Large B-cell Lymphoma (DLBCL).

The poster presentation on Wednesday, April 13th highlights the robust in vivo activity of BTM-3566, including complete and durable regressions in 6 out of 9 PDX models with a 100% response rate across a range of difficult to treat DLBCL tumors. Equally important, BTM-3566 acts through a novel mechanism of action with activity across multiple genomic and phenotypic subtypes of DLBCL, suggesting this represents an impactful treatment option for patients progressing on existing standard-of-care agents. Emerging data characterizing the responses and dependency on expression of a mitochondrial protein will also be presented.

The abstract is available now on the AACR website.

Michael Stocum, CEO of Bantam Pharmaceutical, commented: “We are excited to be presenting this new data at AACR. Together with our academic collaborators, we continue enhancing our understanding of the novel mechanism of BTM-3566 and its capacity to induce apoptosis in cancer cells. We expect to file an Investigational New Drug (IND) application for BTM-3566 this quarter (2Q 2022) and are prepared to initiate clinical trials later this year. Our IND and pre-clinical data are generating significant enthusiasm with oncologists as we advance toward the clinic.”

Title: BTM-3566 co-opts mitochondrial quality control pathways to induce apoptosis, and complete tumor regression in DLBCL cell lines, xenografts and PDX models 

Session Title: Mitochondrial Metabolism in Cancer 

Session Start Time: 4/13/2022 9:00 AM CDT

Location: Poster Section 9 

About BTM-3566

BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique and differentiated from other therapeutics, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being completed for submission in Q2 2022.

About Bantam Pharmaceutical

Bantam Pharmaceutical is a drug discovery and development company channeling the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for its lead candidate, BTM-3566, in B-cell malignancies. Learn more at https://bantampharma.com/.

Company Contact:
Meghan Reynolds, Chief of Staff

View the AACR Poster
We are an early mover in the field of mitochondrial homeostasis, using our pioneering science and unrivaled expertise in mitochondrial cellular biology to revolutionize oncology
We are seeking partners and additional investors to accelerate our clinical research and help bring novel cancer therapies closer to patients in need
Find Out More
Bantam is seeking partners and investors to drive rapid clinical development of our first-in-class molecule from First in Humans trials to clinical Proof of Concept.
Top linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram